Medirom Competitors
| MRM Stock | USD 1.33 0.01 0.76% |
Medirom Healthcare vs Cenntro Electric Correlation
Poor diversification
The correlation between Medirom Healthcare Technologie and CENN is 0.6 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Medirom Healthcare Technologie and CENN in the same portfolio, assuming nothing else is changed.
Moving against Medirom Stock
| 0.94 | GD6 | Ramsay Gnrale de | PairCorr |
| 0.93 | ANCR | Animalcare Group Plc | PairCorr |
| 0.74 | LH | Laboratory | PairCorr |
| 0.71 | X34 | ENHABIT INC DL | PairCorr |
| 0.62 | CI | Cigna Corp | PairCorr |
Medirom Healthcare Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Medirom Healthcare and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Medirom and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Medirom Healthcare does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Medirom Stock performing well and Medirom Healthcare Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Medirom Healthcare's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BYAH | 5.84 | (2.08) | 0.00 | (1.83) | 0.00 | 12.00 | 46.58 | |||
| SOND | 66.40 | 26.46 | 0.85 | (2.09) | 24.50 | 67.74 | 2,000 | |||
| YYGH | 2.97 | (0.40) | 0.00 | (0.18) | 0.00 | 8.33 | 19.52 | |||
| DSS | 4.11 | (0.28) | 0.00 | (0.11) | 0.00 | 12.77 | 50.17 | |||
| BTBD | 3.09 | (0.57) | 0.00 | (0.21) | 0.00 | 6.41 | 22.95 | |||
| ATER | 3.74 | (0.45) | 0.00 | (0.20) | 0.00 | 7.69 | 28.48 | |||
| LOBO | 4.98 | 0.14 | 0.01 | 0.24 | 8.57 | 13.64 | 47.21 | |||
| FLYE | 11.00 | 1.65 | 0.13 | (0.23) | 8.99 | 15.36 | 284.75 | |||
| FGI | 5.68 | 0.26 | 0.05 | 0.16 | 7.49 | 16.30 | 50.77 | |||
| CENN | 4.20 | (0.37) | 0.00 | (0.12) | 0.00 | 13.33 | 24.81 |
Cross Equities Net Income Analysis
Compare Medirom Healthcare and related stocks such as Park Ha Biological, Sonder Holdings, and YY Group Holding Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BYAH | (485 K) | (485 K) | (485 K) | (485 K) | (485 K) | (485 K) | (485 K) | (485 K) | (485 K) | (485 K) | (485 K) | 191.3 K | 852 K | 478.6 K | 478.6 K | 550.3 K | 285.2 K |
| SOND | (178.2 M) | (178.2 M) | (178.2 M) | (178.2 M) | (178.2 M) | (178.2 M) | (178.2 M) | (178.2 M) | (178.2 M) | (178.2 M) | (250.3 M) | (294 M) | (245 M) | (295.7 M) | (295.7 M) | (224.1 M) | (235.3 M) |
| YYGH | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 362.9 K | 761.6 K | 852.3 K | (4.8 M) | (4.4 M) | (4.1 M) |
| DSS | (456.6 K) | (3.2 M) | (4.3 M) | 2.6 M | (41.2 M) | (14.3 M) | (950 K) | (578 K) | 1.5 M | (2.9 M) | 1.9 M | (33.1 M) | (59.8 M) | (60.6 M) | (46.9 M) | (42.2 M) | (40.1 M) |
| BTBD | 255.1 K | 255.1 K | 255.1 K | 255.1 K | 259.5 K | (254.9 K) | (254.9 K) | (254.9 K) | 20.8 K | (368.6 K) | 792 K | 607.9 K | (562.3 K) | (887.4 K) | (2.3 M) | (2.1 M) | (2 M) |
| ATER | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (31.8 M) | (58.8 M) | (63.1 M) | (236 M) | (196.3 M) | (74.6 M) | (11.9 M) | (10.7 M) | (11.2 M) |
| LOBO | 569.5 K | 569.5 K | 569.5 K | 569.5 K | 569.5 K | 569.5 K | 569.5 K | 569.5 K | 569.5 K | 569.5 K | 569.5 K | 1.6 M | 1.1 M | 969.6 K | (812.8 K) | (731.6 K) | (695 K) |
| FLYE | 408 K | 408 K | 408 K | 408 K | 408 K | 408 K | 408 K | 408 K | 408 K | 408 K | 408 K | 408 K | 1.4 M | 1.9 M | (5.3 M) | (4.8 M) | (4.5 M) |
| FGI | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 4.7 M | 7.9 M | 3.7 M | 733.6 K | (1.2 M) | (1.1 M) | (1 M) |
| CENN | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (21.1 M) | (19.1 M) | (10.8 M) | (5.8 M) | (33.8 M) | (19.5 M) | (5.2 M) | (16.4 M) | (110.1 M) | (54.2 M) | (44.9 M) | (40.4 M) | (42.4 M) |
Medirom Healthcare and related stocks such as Park Ha Biological, Sonder Holdings, and YY Group Holding Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Medirom Healthcare financial statement analysis. It represents the amount of money remaining after all of Medirom Healthcare Technologies operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Medirom Healthcare Competitive Analysis
The better you understand Medirom Healthcare competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Medirom Healthcare's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Medirom Healthcare's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Medirom Healthcare Competition Performance Charts
Five steps to successful analysis of Medirom Healthcare Competition
Medirom Healthcare's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Medirom Healthcare in relation to its competition. Medirom Healthcare's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Medirom Healthcare in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Medirom Healthcare's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Medirom Healthcare, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Medirom Healthcare position
In addition to having Medirom Healthcare in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Volatility ETFs Thematic Idea Now
Volatility ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Volatility ETFs theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Volatility ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Medirom Healthcare Correlation with its peers. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Health Care Providers & Services sector continue expanding? Could Medirom diversify its offerings? Factors like these will boost the valuation of Medirom Healthcare. Expected growth trajectory for Medirom significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Medirom Healthcare data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.278 | Earnings Share 0.39 | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets |
Understanding Medirom Healthcare requires distinguishing between market price and book value, where the latter reflects Medirom's accounting equity. The concept of intrinsic value - what Medirom Healthcare's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Medirom Healthcare's price substantially above or below its fundamental value.
Understanding that Medirom Healthcare's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Medirom Healthcare represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Medirom Healthcare's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.